Presentation is loading. Please wait.

Presentation is loading. Please wait.

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial 

Published byGundi Hummel Modified over 6 years ago

Similar presentations

Presentation on theme: "MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial "— Presentation transcript:

1 MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial  Matthew Hellmann, Scott Antonia, Santiago Ponce, Patrick Ott, Emiliano Calvo, Matthew Taylor, Neal Ready, Christine Hann, Filippo De Braud, Joseph Paul Eder, Dirk Jäger, Paolo Ascierto, Leora Horn, Asim Amin, Jeffry Evans, Victor Moreno, Akin Atmaca, Rathi Pillai, Jaishree Bhosle, Petri Bono, Noemi Reguart, Jeffrey Schneider, Peter Brossart, Jennifer Diamond, Padmanee Sharma, Ulrik Lassen, Chen-Sheng Lin, Marina Tschaika, Giovanni Selvaggi, David Spigel  Journal of Thoracic Oncology  Volume 12, Issue 1, Pages S393-S394 (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, S393-S394DOI: (10. 1016/j. jtho
Copyright © Terms and Conditions

Download ppt "MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial "

Similar presentations

SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
P1.03-040 Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey  Alexis Cortot, Sébastien Couraud,

P Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey  Alexis Cortot, Sébastien Couraud,
P1.08-044 Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies  Maria Echavarria, Anna.

P Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies  Maria Echavarria, Anna.
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.
MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.

MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
P1.08-027 Evolution of Survival in a Regional Population-Based US Lung Cancer Resection Cohort  Raymond Osarogiagbon, Nicholas Faris, Matthew Smeltzer,

P Evolution of Survival in a Regional Population-Based US Lung Cancer Resection Cohort  Raymond Osarogiagbon, Nicholas Faris, Matthew Smeltzer,
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.
MA13.01 Markerless Tumor Tracking during Lung Radiotherapy Using Intrafraction X- Ray Imaging  Chun-Chien (Andy) Shieh, Vincent Caillet, Michelle Dunbar,

MA13.01 Markerless Tumor Tracking during Lung Radiotherapy Using Intrafraction X- Ray Imaging  Chun-Chien (Andy) Shieh, Vincent Caillet, Michelle Dunbar,
P1.05-044 The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort  Matthew Smeltzer,

P The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort  Matthew Smeltzer,
P1.08-022 Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.
P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig.

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig.
P2.04-054 Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)  Taofeek Owonikoko,

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)  Taofeek Owonikoko,

Similar presentations

Ads by Google